3-benzyloxy-N-benzyl-1,2,5,6-tetrahydropyridine | 61995-15-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-benzyloxy-N-benzyl-1,2,5,6-tetrahydropyridine
• 英文别名: 1-benzyl-5-benzyloxy-1,2,3,6-tetrahydro-pyridine；Benzyl-1,2,5,6-tetrahydro-3-pyridyl benzyl ether；1-Benzyl-1,2,5,6-tetrahydro-3-pyridylbenzylether；1-Benzyl-3-(benzyloxy)-1,2,5,6-tetrahydropyridine；1-benzyl-5-phenylmethoxy-3,6-dihydro-2H-pyridine
• CAS: 61995-15-1
• 化学式: C₁₉H₂₁NO
• 分子量: 279.382
• InChiKey: WKMTXDBUDKSLHT-UHFFFAOYSA-N

物化性质

• 熔点：
  55-56 °C
• 沸点：
  434.8±45.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-benzyloxy-N-benzyl-1,2,5,6-tetrahydropyridine 在 水 、 氢溴酸 作用下， 反应 3.0h， 以43%的产率得到1-苄基哌啶-3,3-二醇氢溴酸
  参考文献：
  名称：

  Method of Using Substituted Piperidines that Increase P53 Activity

  摘要：

  本发明揭示了使用具有HDM2蛋白拮抗活性的化合物来治疗或预防癌症、其他由异常细胞增殖引起的疾病、与HDM2相关的疾病或由不足的P53活性引起的疾病的方法。

  公开号：

  US20080004286A1
• 作为产物：
  描述：

  5-(苄氧基)-2-溴吡啶 在 sodium cyanoborohydride 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 88.0h， 生成 3-benzyloxy-N-benzyl-1,2,5,6-tetrahydropyridine
  参考文献：
  名称：

  Synthetic Studies of Substituted Pyridine Aldehydes as Intermediates for the Synthesis of Toddaquinoline, Its Derivatives and Other Natural Products

  摘要：

  The synthesis of substituted 2-bromopyridine aldehydes as intermediates in our planned approach to toddaquinoline, its derivatives and other natural products is reported. The DMF-formylation method of pyridine ring, the Vilsmeier-Haack procedure and the bromination of pyridine ring respectively, were studied in order to synthesize the above mentioned compounds. The successful methods (DMF-formylation and bromination of pyridine ring) provided the 2-bromo-4-formyl-5-tosyloxypyridine Ib and 5-benzyloxy-2,4,6-tribromonicotinaldehyde Ia under relatively mild conditions and in good yields.

  DOI：

  10.3987/com-11-12239

文献信息

• Synthesis of d/l-Febrifugine and d/l-Isofebrifugine
  作者：Yasuo Takeuchi

  DOI：10.1055/s-1999-3583

  日期：1999.10
• METHOD OF USING SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY
  申请人：Schering Corporation

  公开号：EP2037919A2

  公开（公告）日：2009-03-25
• [EN] METHOD OF USING SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY<br/>[FR] PROCÉDÉ D'UTILISATION DE PIPÉRIDINES SUBSTITUÉES QUI AUGMENTENT L'ACTIVITÉ DE P53
  申请人：SCHERING CORP

  公开号：WO2008005266A2

  公开（公告）日：2008-01-10

  [EN] The present invention discloses a method of using compounds, which have HDM2 protein antagonist activity, to treat or prevent cancer, other diseases caused by abnormal cell proliferation, diseases associated with HDM2, or diseases caused by inadequate P53 activity.
  [FR] La présente invention concerne un procédé d'utilisation de composés dotés d'une activité antagoniste vis-à-vis de la protéine HDM2 en vue de traiter ou de prévenir un cancer, d'autres maladies causées par une prolifération cellulaire anormale, des maladies associées à HDM2, ou des maladies induites par une activité de P53 inadéquate.
• Synthetic Studies of Substituted Pyridine Aldehydes as Intermediates for the Synthesis of Toddaquinoline, Its Derivatives and Other Natural Products
  作者：Georgeta Serban、Hitoshi Abe、Yasuo Takeuchi

  DOI：10.3987/com-11-12239

  日期：——

  The synthesis of substituted 2-bromopyridine aldehydes as intermediates in our planned approach to toddaquinoline, its derivatives and other natural products is reported. The DMF-formylation method of pyridine ring, the Vilsmeier-Haack procedure and the bromination of pyridine ring respectively, were studied in order to synthesize the above mentioned compounds. The successful methods (DMF-formylation and bromination of pyridine ring) provided the 2-bromo-4-formyl-5-tosyloxypyridine Ib and 5-benzyloxy-2,4,6-tribromonicotinaldehyde Ia under relatively mild conditions and in good yields.
• Method of Using Substituted Piperidines that Increase P53 Activity
  申请人：Wang Yaolin

  公开号：US20080004286A1

  公开（公告）日：2008-01-03

  The present invention discloses a method of using compounds, which have HDM2 protein antagonist activity, to treat or prevent cancer, other diseases caused by abnormal cell proliferation, diseases associated with HDM2, or diseases caused by inadequate P53 activity.

  本发明揭示了使用具有HDM2蛋白拮抗活性的化合物来治疗或预防癌症、其他由异常细胞增殖引起的疾病、与HDM2相关的疾病或由不足的P53活性引起的疾病的方法。